Corroborating these observations, Roy et al. affirmed that RUNX2 serves as a key gene promoting bone metastasis in prostate cancer by activating the MEK/ERK1/2 signaling pathway [168]. The gene discussed is RUNX2; the disease is prostate carcinoma.